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Animal and laboratory studies suggest that regular use of nonsteroidal anti-inflammatory drugs (NSAIDs) may reduce prostate cancer
risk. To assess this association, we conducted a systematic review and meta-analysis of observational studies published before January
2003. We derived summary odds ratios (ORs) using both fixed and random effects models and performed subgroup analyses to
explore the possible sources of heterogeneity between combined studies. We identified 12 reports (five retrospective and seven
prospective studies). Most studies of aspirin use reported inverse associations, but only two were statistically significant. The summary
OR for the association between aspirin use and prostate cancer was 0.9 (95% confidence interval: 0.82–0.99; test of homogeneity
P¼0.32), and varied from 1.0 for retrospective studies to 0.85 for prospective studies. Studies that measured exposure to a mixture
of NSAIDs were less consistent. These results indicate an inverse association between aspirin use and prostate cancer risk. The
current epidemiological evidence and, in particular, the strong and consistent laboratory evidence underline the need for additional
epidemiological studies to confirm the direction and magnitude of the association.
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Prostate cancer is the most commonly diagnosed noncutaneous
malignancy in the United States (Jemal et al, 2002) and Canada
(National Cancer Institute of Canada, 2000). It is also a major
cause of death from cancer, being second only to lung cancer.
Despite the public health problem posed by prostate cancer, little
is known about its causes. So far, epidemiologic studies have
documented three main risk factors: increasing age, black race,
and family history, none of which is modifiable (Kolonel et al,
1999). Several exposures (e.g. endogenous hormones, fat intake,
obesity, smoking and alcohol consumption, occupational expo-
sures, and physical activity) were extensively investigated with
conflicting or inconclusive results (Hsing, 2001). It is therefore not
surprising that most primary prevention strategies for prostate
cancer are focused on chemoprevention. One chemopreventive
approach that has received attention is the regular use of
nonsteroidal anti-inflammatory drugs (NSAIDs). It is now
generally accepted that NSAIDs prevent the development of
colorectal cancer (Kim et al, 2002), and there is some evidence
for a protective effect for other types of cancer (Khuder and Mutgi,
2001; Corley et al, 2003). Proposed mechanisms of these effects
include induction of apoptosis, inhibition of angiogenesis, and
direct inhibition of cellular growth (Kirschenbaum et al, 2001); all
occur at least partly through inhibition of the cyclooxygenase
(COX) enzymes involved in prostaglandin synthesis. Overexpres-
sion of COX-2 has been observed in human prostate cancer cells
(Gupta et al, 2000), and higher levels of prostaglandins have been
detected in malignant compared to benign prostate tissues
(Chaudry et al, 1994). Further, NSAIDs have been shown to
inhibit prostate cancer cell proliferation and induce apoptosis in
vitro (Liu et al, 1998; Hsu et al, 2000). Thus, the COX enzymes and
the synthesis of prostaglandins may represent new targets for both
chemoprevention and antitumour therapy (Lieberman, 2002).
Several observational epidemiological studies have been pub-
lished on NSAID use and the risk of prostate cancer. Despite fairly
consistent laboratory evidence, none of these studies produced
conclusive results. In order to clarify the possible effect of NSAID
use in the prevention of prostate cancer, we conducted a
systematic review combined with meta-analysis of the relevant
literature. Our aim was to examine both the strength and the
consistency of the association between NSAID use and prostate
cancer and to explore sources of variation between studies. In
additional, we examined the evidence for dose–response and
duration–response effects.
MATERIALS AND METHODS
Search strategy
We identified relevant studies and abstracts by searching Medline,
preMedline, Biosis, and Cancerlit for studies published before
January 2003. We also searched the Web of Science and the
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lCochrane Collaboration Controlled Trials Register. We used the
following search terms: ‘prostate’, ‘prostate cancer’, ‘prostatic
neoplasms’, ‘aspirin’, ‘anti-inflammatory agents’, ‘NSAID’, and
‘NSAID*’. In addition, we searched the proceedings of the
American Association for Cancer Research meetings for the years
1990–2002, and screened the bibliographies of identified publica-
tions for additional citations.
Studies were included if they met two criteria: (1) the exposure
measured was the use of any particular NSAID or mixture of
NSAIDs, and (2) the outcome considered was the incidence of
prostate cancer. Otherwise, we did not impose any exclusion
criteria. We independently reviewed all studies for inclusion, and
used a specially designed data extraction form to aid consistent
recording of data from all studies. Data were extracted indepen-
dently and discrepancies in data abstraction were resolved through
consensus.
We sought the following information from each article: authors;
journal and year of publication; geographic region; study design;
number and characteristics of prostate cancer cases and controls
(or population); period and duration of recruitment and/or follow-
up; type of NSAID; and method of data collection (interview,
questionnaire, or database). When available, covariate-adjusted
relative risk (RR) estimates (rate ratios or odds ratios (ORs)
depending on study type) were extracted and used in the meta-
analysis. Whenever complete information on the RRs was missing
in a published report, we obtained the pertinent data directly from
the original investigators.
Statistical analysis
We derived summary ORs using both fixed (Mantel–Haenszel
method) and random effects models (DerSimonian–Laird meth-
od), but reported summary ORs from the latter only (Berlin et al,
1989). Random models take into account both the sampling
variance within the studies and the variation in the underlying
effect across studies. The assumption of variation in the underlying
effect seems plausible given the different populations, study
designs, drug types, and exposure assessment methods used in
the original studies. We used the Cochran’s Q test to assess the
consistency (homogeneity) of the summary measures. A P-value of
o0.1 was interpreted as evidence of greater heterogeneity among
the combined studies than what would be expected by chance
alone.
We performed subgroup analyses to explore the possible
sources of observed heterogeneity between the combined studies
(Egger et al, 1997b). These analyses comprised calculating
summary ORs for subsets of studies defined by certain study
characteristics, such as study design (retrospective vs prospective
according to the timing of exposure assessment; that is, before or
after diagnosis), the outcome examined (advanced cancers (lesions
with extracapsular extension or metastases to regional lymph
nodes or other organs) vs total prostate cancer (all cancers
regardless of stage)), drug type (aspirin, nonaspirin NSAIDs (NA-
NSAIDs), or all NSAIDs), period of recruitment (before or after
1990; the introduction of PSA testing), and geographic region
(USA vs others). We also used metaregression to model the effects
of these factors on change in summary ORs (Berkey et al, 1995).
The weighted linear regression model that we employed relates the
risk of prostate cancer to the study-level covariates, assuming a
normal distribution for the residual errors with both within-study
and between-studies components. Between-studies variance (t
2)
was estimated using the restricted maximum-likelihood method.
In addition, we used funnel plots and Begg’s (Begg and Mazumdar,
1994) and Egger’s tests (Egger et al, 1997a) to examine the evidence
for publication and other selection biases, and performed
sensitivity analyses to detect influential studies. All analyses were
conducted using Stata (Stata Corporation, version 8, College
Station, TX, USA, 2003). All P-values are two-tailed.
RESULTS
We identified 12 reports (10 manuscripts and two unpublished
reports) that met the inclusion criteria (Paganini-Hill et al, 1989;
Schreinemachers and Everson, 1994; Neugut et al, 1998; Norrish
et al, 1998; Langman et al, 2000; Nelson and Harris, 2000; Habel
et al, 2002; Irani et al, 2002; Leitzmann et al, 2002; Menezes et al,
2002; Roberts et al, 2002; Perron et al, 2003). Two other studies
were excluded because they evaluated outcomes other than
incident prostate cancer: a case–control study that measured the
prevalence of prostate cancer in autopsies of analgesics abusers
(OR¼0.84; 95% confidence interval (CI): 0.36–1.98) (Bucher et al,
1999) and a cohort study that measured mortality from male
genital cancers (rate ratio¼0.82; 95% CI: 0.56–1.19) (Thun et al,
1993).
The characteristics of the 12 included studies are summarised in
Table 1. These were retrospective five and seven prospective
Table 1 Characteristics of reviewed studies
Study (year of
publication) Country Design
Total no.
of cases
Mean age
(years)/
(range) Outcome Drug type
Exposure
prevalence (%)
Period of
recruitment
Source
of info
Irani et al (2002) France Case–control 639 66.8 PC total NA-NSAIDs/aspirin 76 1999–2000 Interview
Menezes et al (2002) USA Case–control 1096 — PC total Aspirin — 1992–1998 Questionnaire
Nelson and Harris (2000) USA Case–control 417 64 PC total NSAIDs/NA-NSAIDs — 1992–1995 Interview
a
Neugut (1998) USA Case–control 319 69 PC total Aspirin 24 1984–1986 Medical notes
Norrish et al (1998) New
Zealand
Case–control 317 70 PC total/adv NSAIDs/
NA-NSAIDs/aspirin
51 1996 Questionnaire
Habel et al (2002) USA Cohort 2574 18–84 PC total/adv Aspirin 2.7 1964–1996 Questionnaire
Leitzmann et al (2002) USA Cohort 2479 40–75 PC total/adv Aspirin — 1986–1998 Questionnaire
Paganini-Hill et al (1989) USA Cohort 149 73 PC total Aspirin 31 1981–1988 Questionnaire
Roberts et al (2002) USA Cohort 91 64 PC total NSAIDs 42 1990–1996 Interview
Schreinemachers
and Everson (1994)
USA Cohort 123 65 PC total Aspirin 59 1971–1987 Interview
Langman et al (2000) UK Nested
case–control
1813 — PC total NSAIDs 25 1993–1995 Database
Perron et al (2003) Quebec Nested
case–control
2221 75.7 PC total NA-NSAIDs/aspirin 42 1993–1996 Database
PC=prostate cancer; Adv¼advanced prostate cancer (cancers with extracapsular extension or metastases to regional lymph nodes or other organs); NSAID¼nonsteroidal
anti-inflammatory drug; NA-NSAID¼nonaspirin NSAID.
aSupplemented by medical notes.
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lstudies including two nested case–control studies. There were no
randomised trials. With regard to the type of NSAID, nine studies
measured exposure to aspirin, whereas four reported RRs for all
NSAIDs (NSAIDS) and four studies reported RRs for use of NA-
NSAIDS. Most studies were carried out in North America (eight in
the USA and one in Quebec, Canada) and during the 1990s. In
most studies, drug use was assessed once only, typically by asking
subjects about their average intake over a period of time, which
ranged from 30 days (Schreinemachers and Everson, 1994) to 5
years (Irani et al, 2002), prior to interview or diagnosis. Two and
four assessments, respectively, were carried out during follow-up
in the cohort studies described by Roberts et al and Leitzmann
et al. Perron et al, using Quebec’s drug claims database, had
information on all NSAIDs prescribed on an outpatient basis to
persons aged 65 years and older. None of the reviewed studies had
adequate information on the time since first use or duration of use.
Figure 1 shows RRs and 95% CIs from the included studies
stratified by drug type and outcome. Most studies of aspirin use
reported RRs less than 1, but only two were statistically significant.
Except for one large prospective study, studies of NA-NSAIDs
reported inverse associations. Studies of NSAIDs were less
consistent; one study found a positive association; and another
reported a weak inverse association, whereas two studies reported
a strong inverse association that ranged between 0.34 and 0.45.
Table 2 presents the results of subgroup analyses. Relative risks
were combined by NSAID type, outcome, and study design. For
aspirin, there were three studies that reported RRs for advanced
prostate cancer; all reported very similar estimates resulting in a
summary OR of 0.7 (95% CI: 0.52–0.94; test of homogeneity
P¼0.97). The summary OR for the nine studies that assessed the
effect of aspirin on total prostate cancer was 0.9 (95% CI: 0.82–
0.99; test of homogeneity P¼0.32). Heterogeneity was further
reduced when we combined studies by design type. The summary
OR for retrospective studies was 1.0 (test of homogeneity P¼0.33)
while that of prospective studies was appreciably lower at 0.85
(95% CI: 0.77–0.94), with no evidence of significant heterogeneity
(test of homogeneity P¼0.71). When we combined studies by
country of origin, the six studies from the USA gave a summary
OR of 0.94 (95% CI: 0.82–1.1), whereas the other three studies
(from Canada, England, and New Zealand) gave a lower and
statistically significant summary OR of 0.85 (95% CI: 0.76–0.96).
Using metaregression modelling, USA studies had a higher
summary OR by an average of 0.32 (95% CI: 0.02–0.62; P¼0.04)
even after adjusting for study design, length of follow-up, and
Leitzmann (USA)
Habel (USA)
Norrish (New Zealand)
Habel (USA)
Leitzmann (USA)
Paganini-Hill (USA)
Schreinemachers (USA)
Perron (Canada)
Neugut (USA)
Menezes (USA)
Norrish (New Zealand)
Irani (France)
Perron (Canada)
Nelson (USA)
Irani (France)
Norrish (New Zealand)
Roberts (USA)
Langman (UK)
Nelson (USA)
Norrish (New Zealand)
All studies of advanced PC 
Prospective studies combined
Retrospective studies combined
Total PC combined
NA-NSAIDs combined
NSAIDs combined
A. Aspirin
A.1. Studies of advanced PC
A.2. Studies of total PC
A.2.1. Prospective studies
A.2.2. Retrospective studies
B. NA-NSAIDs
C. NSAIDs
  Q=0.07(3) p=0.967
  Q=2.12(5) p=0.713
  Q=3.46(4) p=0.326
  Q=9.31(9) p=0.317
  Q=12.65(4) p= 0.005
  Q=33.41(54) p<0.001
0.63
0.71
0.71
0.70
0.76
0.91
0.95
0.95
0.82
0.85
1.60
1.08
0.85
0.95
1.01
0.90
1.20
0.35
0.84
0.87
0.87
0.45
1.33
0.34
0.88
0.67
0.27-1.46
0.45-1.13
0.47-1.08
0.52-0.94
0.59-0.97
0.75-1.10
0.60-1.51
0.66-1.36
0.71-0.95
0.77-0.94
0.82-3.12
0.87-1.35
0.61-1.19
0.75-1.20
0.86-1.18
0.82-0.99
1.02-1.41
0.15-0.83
0.66-1.07
0.49-1.55
0.61-1.23
0.28-0.73
1.07-1.65
0.20-0.58
0.64-1.20
0.37-1.22
Study (country) Heterogeneity OR 95%CI
Odds ratio
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Figure 1 Relative risk estimates and summary ORs by NSAID type.
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lmethod of exposure assessment. The between-trial variance (t
2)
for this model was very small, indicating that most between-study
variability was explained by these four variables. After adjusting
for geographic region, which had the strongest influence on the
summary OR, all the other variables that we modelled (study
design, method of exposure assessment, recruitment period, mean
age of study population, adjustment for detection bias, and
prevalence of aspirin use) had virtually no effect on the summary
OR.
For studies that measured exposure to NA-NSAIDs, the
summary OR was 0.87 (95% CI: 0.61–1.24) with substantial
heterogeneity between studies (P¼0.005). Heterogeneity was
primarily caused by the inclusion of a large Canadian prospective
study (Perron et al, 2003) that reported an OR of 1.2 (95% CI:
1.02–1.4) for NA-NSAID use. Excluding this study, the summary
OR is 0.73 (95% CI: 0.49–1.1) and heterogeneity is greatly reduced
(P¼0.151). The four studies that assessed NSAIDs intake showed
no consistent association with prostate cancer even after stratify-
ing by study design.
Most studies lacked information on dose and duration of NSAID
use. The largest benefit was seen among those who used aspirin for
more than 22 days/month in one study (Leitzmann et al, 2002),
and among those who consumed more than one pill per day in
another (Nelson and Harris, 2000). Yet, other studies found no
evidence of a dose–effect relationship. (Paganini-Hill et al, 1989;
Norrish et al, 1998; Langman et al, 2000). The study that was best
equipped to address this issue (Perron et al, 2003), in terms of
power and availability of detailed exposure data, reported a
stronger inverse association with larger doses of aspirin, but only
among participants who used aspirin for X4 years. This study also
found a negative trend of prostate cancer risk with duration of use;
the ORs decreased from about 1 for p4 years of use to 0.66 for
men who used aspirin for X6 years.
Table 3 presents the results of influence analysis for aspirin use
and total prostate cancer. To estimate the influence of individual
studies, the summary ORs were computed omitting one study at a
time. The summary ORs were reasonably stable ranging from 0.87,
when the study by Menezes et al was excluded, to 0.93 when the
study of Perron et al was excluded. There was little evidence of
heterogeneity in the funnel plots or in any of the statistical tests
that we performed to assess for publication bias (Kendall’s
score¼12, Begg’s test P¼0.5; Egger’s test P¼0.46).
DISCUSSION
The results of this review suggest that aspirin use was inversely
related to the risks of developing prostate cancer. The association
was stronger for advanced cancers (summary OR¼0.7) than for
total prostate cancers (summary OR¼0.9). However, the latter
finding was not consistent; the estimates varied by study design
and geographic region. Retrospective studies and studies carried
out in the USA showed no association, whereas prospective studies
and studies from outside the USA pointed to a statistically
significant inverse association. One possible explanation for the
lack of association with retrospective studies is detection bias since
aspirin users are more likely to be screened for prostate cancer
because of the more frequent contact with health-care providers
(Leitzmann et al, 2002; Roberts et al, 2002). In this review, only
three studies attempted to control for detection bias; and they were
all prospective studies. Detection bias may also explain the
observed reduction in advanced prostate cancer among aspirin
users, as these patients are more likely to be diagnosed at earlier
stages. USA studies may have weaker associations due to higher
levels of PSA screening rendering them more susceptible to
detection bias than studies carried out elsewhere. When the
investigators from an American prospective study restricted
analyses to those men who have had PSA testing, their RR
estimate for total prostate cancer dropped from 1.04 to 0.91
(Leitzmann et al, 2002).
Another possibility, which is always a source of concern in
meta-analyses, is publication bias. Most prospective studies in this
review were not specifically designed to examine the effects of
aspirin on prostate cancer and therefore many of the reported
analyses were performed using precollected data. It is conceivable
that investigators from these studies were less likely to report their
results if they found no beneficial effects (the file drawer problem,
Rosenthal, 1979). Retrospective studies, on the other hand, tended
to be designed to examine this association and perhaps were less
susceptible to the problem. There was, however, no evidence of
publication bias in any of the graphical and statistical tests that we
performed.
Retrospective studies are also prone to misclassification in the
measurement of NSAID use, especially if they relied on subject
report. In fact, exposure misclassification may have played an
important role in many of the studies examined in this review
Table 2 Summary ORs of prostate cancer by NSAID type
Study characteristics No. of studies
Summary OR – random model Heterogeneity
OR 95% CI P-value QP -value
Aspirin
Studies of advanced prostate cancer 3 0.70 0.52–0.94 0.016 0.07 0.967
Studies of total prostate cancer 9 0.90 0.82–0.99 0.025 9.31 0.317
Prospective studies of total prostate cancer 5 0.85 0.77–0.94 0.001 2.12 0.713
Prospective studies of total prostate cancer that corrected for detection bias 3 0.84 0.75–0.93 0.001 1.42 0.492
Retrospective studies of total prostate cancer 4 1.01 0.86–1.18 0.949 3.46 0.326
Studies of total prostate cancer in the USA 6 0.94 0.82–1.09 0.415 6.95 0.224
Studies of total prostate cancer in other countries 3 0.85 0.76–0.96 0.008 1.09 0.58
NA-NSAIDS
Studies of total prostate cancer 4 0.87 0.61–1.24 0.433 12.65 0.005
Studies of total prostate cancer excluding Perron et al 3 0.73 0.49–1.10 0.133 3.78 0.151
NSAIDs
Studies of total prostate cancer 4 0.68 0.37–1.22 0.192 33.41 o0.001
Prospective studies of total prostate cancer 2 0.79 0.27–2.29 0.665 16.40 o0.001
Retrospective studies of total prostate cancer 2 0.56 0.22–1.42 0.223 9.09 0.003
OR¼odds ratio; CI¼confidence interval; NSAID¼nonsteroidal anti-inflammatory drug; NA-NSAID¼nonaspirin NSAID.
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which was repeatedly shown to be relatively poor for nonrepetitive
NSAID use (West et al, 1997). Many prospective studies measured
NSAID use only once (at entry), or collected information on
aspirin but not other NSAIDs, or restricted information collection
to heavy users. These limitations could result in significant errors
in measurement that may have attenuated or masked any
beneficial effects of NSAID use. Studies that used prescription
databases lacked information on nonprescription use (e.g. over the
counter use) and were based on the assumption that the amount of
NSAIDs dispensed is a good approximation of actual consumption.
This may not be true especially for NSAIDs other than aspirin that
are frequently prescribed to be taken only when needed (Perron
et al, 2003). More importantly, in most studies exposure was
simply categorised as ‘ever use’ or ‘frequent use’ vs ‘never use’.
This approach is unlikely to capture biologically plausible effects
of drug use given the brief and noncumulative pharmacologic
effects of NSAIDS and the slowly evolving nature of prostate
cancer. Any potential effects of NSAID use are likely to involve
considerable induction periods (estimated to be 10–15 years for
colon cancer). Consequently, using cumulative measures of
exposure that span the whole follow-up time may dilute the
estimated effects because such measures combine both aetiologi-
cally relevant and irrelevant exposures (Rothman and Greenland,
1998). Ideally, exposure to NSAIDs should be characterised as the
average rate of consumption during a specific period before
diagnosis. Moreover, the effect estimate for exposure during a
specific period should be mutually adjusted for confounding by
exposure in other periods.
Confounding is another important consideration when evaluat-
ing observational studies. Both NSAID use and prostate cancer risk
increase with age; hence, all studies adjusted for age. Many studies
adjusted for race and many environmental and lifestyle factors
(e.g. diet, obesity, physical activity, intake of vitamins and
minerals), which could be distributed differently among aspirin
users (Cook et al, 2000), and may therefore account for the
association. Generally, the multivariate-adjusted estimates were
similar to the age-adjusted estimates, indicating that perhaps none
of these factors is a significant confounder. However, residual
confounding cannot be ruled out as an alternative explanation.
Another type of confounding specific to observational studies of
drug exposures is ‘confounding by indication’ that occurs when
drug use is also a marker of a disease or condition that increases or
decreases the risk of the outcome under study (Psaty et al,
1999). Nonsteroidal anti-inflammatory drugs are widely used
in the treatment of rheumatic arthritis, osteoarthritis, and
other rheumatic conditions. Aspirin is also used in the primary
and secondary prevention of coronary heart disease. There are
very few studies that examined the association between these
conditions and prostate cancer, and they were generally indicative
of a small increase in risk among those patients (Gridley et al,
1993; Thomas et al, 2000). There is no evidence that any of the
indications of NSAID use is inversely associated with prostate
cancer risk such that a spurious beneficial effect is created.
However, we cannot totally exclude the possibility that earlier
mortality among NSAID users (e.g. from heart disease) may
preclude diagnosis of prostate cancer and therefore produce an
apparent beneficial effect.
There is strong and consistent evidence from animal and
laboratory studies that supports a protective role of NSAIDs
against prostate cancer. Research has implicated the COX
enzymes, the enzymatic target of NSAID action, in mediating
prostate carcinogenesis. COX-2 overexpression has been demon-
strated repeatedly in prostate cancer and in prostate intraepithelial
neoplasia (Gupta et al, 2000; Madaan et al, 2000), and is higher in
poorly differentiated tumours (Madaan et al, 2000). The perox-
idase component of COX, also blocked by NSAIDs, can oxidise
many chemical carcinogens, for example, heterocyclic and
aromatic amines (Kirschenbaum et al, 2001). Enhanced synthesis
of prostaglandins, a consequence of COX-2 upregulation, favours
the growth of malignant cells by increasing cell proliferation and
inhibiting immune surveillance (Kirschenbaum et al, 2001).
Chaudry et al (1991) showed that malignant prostate tissue
converts arachidonic acid to PGE2 at a 10-fold higher rate than
benign tissues. In animal studies, several NSAIDs stimulate
apoptosis in prostate cancer cells. Selective COX-2 inhibitors such
as NS398 and celecoxib induce apoptosis in prostate cancer cells
(Liu et al, 1998; Hsu et al, 2000), but not in normal cells. COX-2 is
also implicated in angiogenesis; COX-2 overexpression induces the
production of vascular endothelial growth factor (VEGF), suggest-
ing that COX-2 promotes progression, in part, by inducing
angiogenesis. NS398 inhibits VEGF production and decreases
angiogenesis in PC-3 prostate cancer cells (Liu et al, 2000). These
observations may explain the stronger negative associations
between aspirin use and advanced prostate cancer seen in this
review.
This review is potentially limited in at least three ways. First, our
search was restricted to studies published in indexed journals or in
certain trial registers and conference proceedings. We did not
search for unpublished studies or for original data. However, we
did not impose any exclusion criteria with regard to language or
place of publication, and we assessed, using different approaches,
the potential heterogeneity caused by publication bias. Second,
the included studies were different in terms of design, population,
Table 3 Results of influence analysis for aspirin and total prostate cancer
Study omitted OR 95%CI
Habel 0.92 0.84 1.00
Leitzmann 0.91 0.81 1.01
Paganini-Hill 0.90 0.82 1.00
Schreinemachers 0.90 0.82 1.00
Perron 0.93 0.84 1.03
Neugut 0.89 0.82 0.96
Menezes 0.87 0.80 0.95
Norrish 0.91 0.82 1.01
Irani 0.90 0.81 1.00
Combined 0.90 0.82 0.99
OR= oddsratio;CI = confidence interval.
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all studies and instead tried to explore sources of heterogeneity
using subgroup and metaregression analyses driven by a small
number of a priori hypotheses. However, the summary effect
estimates for NA-NSAIDs and NSAIDs are based on sparse and
heterogeneous data, and therefore should be interpreted with
caution. Third, because of lack of data, we could not address the
issue of the dose and duration of use needed to achieve favourable
effects.
In conclusion, our meta-analysis of available studies indicates
an inverse association between aspirin use and prostate cancer
risk, but the strength of the association varied by study design and
geographic region. Most studies were limited by exposure
misclassification, by limited information on dose and duration of
use, and by the possibility of uncontrolled detection biases. As
most of these biases and errors tend to attenuate or reverse any
beneficial effects of aspirin use, our findings add support to the
hypothesis that aspirin use offers protection against prostate
cancer. The current epidemiological evidence and, in particular,
the strong and consistent laboratory evidence underline the need
for additional epidemiological studies with adequate exposure
measurements, attention to latency effects, and careful adjustment
for detection bias.
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